期刊文献+

奥沙利铂联合氟尿嘧啶/亚叶酸钙一线治疗转移性大肠癌2周方案与3周方案的对比研究 被引量:2

Comparison of 2-week regimen and 3-week regimen based on oxaliplatin plus 5-fluorouracil and Calcium folinate as the first-line in the treatment of metastatic colorectal cancer
下载PDF
导出
摘要 目的:比较奥沙利铂(L-OHP)联合5-氟尿嘧啶/亚叶酸钙(5-FU/CF)的2周方案与3周方案一线治疗转移性结直肠癌的临床疗效及不良反应。方法:66例转移性结直肠癌患者随机接受治疗。A组,予L-OHP85mg/m^2,第1天,静脉滴注2h,同时或之后予CF200mg/m^2,静脉滴注2h,续5-FU400mg/m^2,静脉推注,600mg/m^2持续静脉滴注22h,次日重复CF与5-FU。每2周重复1次,每2次计为1周期。B组,予L-OHP130mg/m^2,第1天,静脉滴注2h,CF200mg/m^2,静脉滴注2h,续5-FU375-425mg/m^2静脉滴注4-6h,连用5d,每3周重复1次,每次计为1周期。结果:A、B两组疗效相近,RR分别为42.9%和38.7%(P〉0.05)。两组病例不良反应发生率相似,主要表现为消化道反应、神经系统毒性和脱发。结论:L-OHP联合5-FU/CF的2周方案与3周方案均可作为晚期转移性大肠癌一线治疗的选择之一。 AIM: To compare the efficacy and adverse reaction of oxaliplatin (L-OHP) in first-line chemotherapy of metastatic colorectal cancer(MCC) combined with infusional 5-fluorouracil (5-FU) and Calcium folinate (CF) administered every. 2 weeks (FOL- FOX4 regimen) or every. 3 weeks. METHODS: 66 previously untreated MCC patients were randomized in two chemotherapy regimen group: grouop A, oxaliplatin 85 mg/m^2 on first day, CF 200 mg/m^2 infusion 2 h followed by bolus 5-FU 400 mg/m^2 and a 22 h infusion of 5-FU 600 mg/m^2, repeated for 2 consecutive days every 2 weeks, group B, oxaliplatin 130 mg/m^2 on first day, CF 200 mg/m^2 infusion 2 h followed by a 4 - 6 h infusion of 5-FU 375-425 mg/m^2, repeated for 5 consecutive days every 3 weeks. RESULTS: The two regimens have similar efficacy, the response rate of group A and B was 42.9 % and 38.7 % respectively ( P 〉 0.05). The adverse reaction rates of the two regimen were no statistical difference. CONCLUSION: The 2- week regimen and the 3-week regimen of L-OHP combined with 5-FU/CF have the same efficacy in MCC patients.
出处 《中国临床药理学与治疗学》 CAS CSCD 2008年第8期930-933,共4页 Chinese Journal of Clinical Pharmacology and Therapeutics
关键词 奥沙利铂 5-氟尿嘧啶/亚叶酸钙 一线治疗 转移性结直肠癌 2周方案 3周方案 oxiplatin 5-fluorouracil and calcium folinate the first-line chemotherapy metastatic colorectal cancer 2-week regimen 3-week regimen
  • 相关文献

参考文献13

  • 1郁宝铭.大肠癌化学治疗的进展[J].中国癌症杂志,2004,14(5):401-405. 被引量:18
  • 2Royce ME, Medgyesy D, Zukowski TH, et al. Colorectal cancer: chemotherapy treatment overview [J]. Oncologgy, 2000, 14(Suppl 14) :40 - 46.
  • 3Chu E. Lessons learned from the saltz and mayo clinic regimens[J]. Clin Colorectal Cancer, 2002,2( 1 ) : 13.
  • 4Piedbois P, Michiels S. Survival benefit of 5 Fu/LV over 5Fu bolus in patients with advanced eoloreetal cancer: An updated meta-analysis based on 2751 patients [ J ]. Proc Am Soc Clin Oncol, 2003,22 : 294.
  • 5Parkin DM, Bray F, Ferlay J. Global cancer statistics 2002 [J]. CA Cancer J Clin, 2005,55(2) :74- 108.
  • 6董志伟,乔友林,李连弟,陈育德,王润田,雷通海,饶克勤,王汝宽,赵平,游伟程,鲁凤珠,戴旭东,王国清,罗贤懋,周海城.中国癌症控制策略研究报告[J].中国肿瘤,2002,11(5):250-260. 被引量:349
  • 7Raymond E, Fairvre S, Woynarowski JM, et al. Oxaliplatin: mechanism of action and antineoplastis activity [J]. Semin Oncol, 1998,25(2 suppl 5) :4- 12.
  • 8Bleiberg H. Oxaliplatin (L-OHP) : a new reality in colorectal cancer[J]. Br J Cancer, 1998,77(4) : 1 - 3.
  • 9Ravaioli A, Marangolo M, Pasquini E, et al. Bolus fluorouracil and leucovorin with oxaliplatin as first-line treatment in metastatic colorectal cancer [ J ]. J Clin Oncol, 2002,20(10) :2545 - 2550.
  • 10Giacehetti S, Perpoint B, Zidani R, et al. Phase Ⅲ multicenter randomized trial of oxaliplatin added to chronomod- ulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer[J]. J Clin Oncol, 2000, 18( 1 ) :136 - 147.

二级参考文献31

  • 1李连弟,鲁凤珠.1990—1992年中国恶性肿瘤死亡流行分布情况分析[J].中华肿瘤杂志,1996,18(6):403-407. 被引量:226
  • 2李连弟,鲁凤珠,张思维,牧人,孙秀娣,皇甫小梅,孙杰,周有尚,欧阳宁慧,饶克勤,陈育德,孙爱明,薛志福,夏毅.中国恶性肿瘤死亡率20年变化趋势和近期预测分析[J].中华肿瘤杂志,1997,19(1):3-9. 被引量:869
  • 3Higgens GA, Amadeo JH. Mc Elhinney J, et al. Efficacy of prolonged intermittent therapy combined 5 - fluorouracil and methyl - CCNU following resection for carcinoma of the large bowel [J] .Cancer,1984,53(1):1 - 8.
  • 4Rougier P, Sahmoud T, Nitti D, et al. Adjuvant portal-vein infusion of fluorouracil and heparin in colorectal cancer: a randomised trial. European Organisation for Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group, the Grupp
  • 5James RD. Intraportal 5-FU (PVI) and peri-operative radiotherapy (PT) in the adjuvant treatment of colorectal cancer ( CRCa) 3681 patients randomized in the UK. Coordination Committee on Cancer Research ( UKCCCR ) AXIS trial[C].Proc Am Soc Clin Oncol, 199
  • 6McArdle C, Kerr DJ, Ledermann JA, et al. Intravenous (IV) vs intrahepatic arterial (IHA) 5-FU/leucovorin for colorectal (CRC) liver metastases: preliminary results of the MRC CR05/EORTC 40972 randomised trial[C].Proc Am Soc Clin Oncol,2001,20:Abstract 499
  • 7Lorenz M, Muller HH. Randomized. multicenter trial of fluorouracil pins leucovorin administered either via hepatic arterial or intravenous infusion versus fluorodeoxyuridine adminstered via hepatic arterial infusion in patients with nonresctable liver met
  • 8Sadahiro S, Suzuki T, Tokunaga N. et al. Prophylactic hepatic arterial infusion chemotherapy for colon cancer patients without liver metastasis provides survival benefit[C].Proc Am Soc Clin Oncol,2001,20:Abstract 510.
  • 9Sakamoto J, Hamada C, Yasutomi M, et al. Adjuvant therapy with oral luormated pyrimidines after curative resection for colorectal cancer: individual patient data meta-analysis of randomized trials[C].Proc Am Sic Clin Oncol,2001,20 Abstract 583.
  • 10Levin J, Schilsky R, Burns H, et al. North American phase III study of oral eniluracil (EU) Plus oral 5-fluoronacil (5-FU) versus intravenous (IV) 5-FU plus leucovorin (LV) in the treatment of advanced colorectal cancer (ACC) [C].Proc Am Soc Clin Oncol, 2

共引文献707

同被引文献10

引证文献2

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部